819869-77-7

Basic information

• Product Name: DOTA-mono-NHS-tris(t-Bu ester)(B-270)
• Synonyms: DOTA-mono-NHS-tris(t-Bu ester)(B-270);DOTA-Mono-NHS-tris(t-Bu ester);1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid, 10-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]-, tris(1,1-diMethylethyl) ester;DOTA-tris-tBu-ester NHS;1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid, 4,7,10-tris(1,1-dimethylethyl) 1-(2,5-dioxo-1-pyrrolidinyl) ester
• CAS NO: 819869-77-7
• Molecular Formula: C₃₂H₅₅N₅O₁₀
• Molecular Weight: 669.8066
• Mol File: 819869-77-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 686.8±65.0 °C(Predicted)
• Appearance: /
• Density: 1.21±0.1 g/cm3(Predicted)
• PKA: 5.49±0.20(Predicted)
• CAS DataBase Reference: DOTA-mono-NHS-tris(t-Bu ester)(B-270)(CAS DataBase Reference)
• NIST Chemistry Reference: DOTA-mono-NHS-tris(t-Bu ester)(B-270)(819869-77-7)
• EPA Substance Registry System: DOTA-mono-NHS-tris(t-Bu ester)(B-270)(819869-77-7)

Safety Data

• Hazardous Substances Data: 819869-77-7(Hazardous Substances Data)

Usage

General Description

DOTA-mono-NHS-tris(t-Bu ester)(B-270) is a chemical compound commonly used in the field of chemistry and biochemistry. It is a derivative of the popular chelating agent DOTA, and contains a mono-NHS (N-Hydroxysuccinimide) functional group which is often used for the modification of biomolecules. The tris(t-Bu ester) groups provide protection for the molecule and can be cleaved under mild conditions to expose the reactive NHS esters. DOTA-mono-NHS-tris(t-Bu ester)(B-270), also known as B-270, is used in the synthesis of radiopharmaceuticals for imaging and targeted therapy, as well as in the development of drug delivery systems and diagnostic assays. Additionally, it is an important reagent in the study of protein interactions and for the conjugation of biomolecules to various substrates.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 137076-54-1 1,4,7-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid 
• 825625-07-8 tri-tert-butyl 2,2’,2’‘-(10-(2-ethoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate 
• 122555-91-3 1,4,7-tris-tert-butoxycarbonylmethyl-1,4,7,10-tetraazacyclododecane 
• 60239-18-1 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 294-90-6 1,4,7,10-tetraazacyclododecan 
• 192635-89-5 phenylmethyl 2-(1,4,7,10-Tetraaza-4,7,10-tris(((tert-butyl)oxycarbonyl)methyl)cyclododecyl)-acetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 

Downstream Products

• 170908-81-3 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(N-hydroxysuccinimidyl ester) 

Relevant articles and documents

RGD-cyclam conjugate: Synthesis and potential application for positron emission tomography

Cyclam and DOTA-containing positron emission tomography radiotracers were prepared by using a modular chemical strategy based on peptide synthesis and chemoselective ligations. These molecules encompass two functional domains, one a tumour 'homing' domain and the other a chelating ligand for copper allowing nuclear imaging of tumours.

Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy

Multivalent conjugates comprising the following formula: (STxB-linker A-S)x-GNS-(S-linker B-T)y wherein STxB is the B-subunit of Shiga toxin; linker A is a noncleavable linker; linker B is a cleavable linker used to release at least

LDL-based nanoparticles for contrast enhanced MRI of atheroplaques in mouse models

A LDL particle functionalized with a GdDO3A-monoamide chelate with a long alkenyl anchor (GdDO3A-OA) was prepared for in vivo detection of atheroplaques. The GdDO3A-OA, when successfully intercalated into the lipid layer of LDL particles, led to a signifi